Patient characteristics and outcome
| Variable . | Patients (n = 23) . |
|---|---|
| Sex: male/female (ratio) | 12/11 (1.1) |
| WM characteristics | |
| Age at WM diagnosis, median (range), y | 58 (35-72) |
| MYD88L265P mutation | 12/14 (86) |
| CXCR4 mutation | 2/8 (25) |
| Number of lines for WM, median (range) | 1 (0-4) |
| HT characteristics | |
| Age at HT, median (range), y | 65 (41-81) |
| Histology | |
| DLBCL, not otherwise specified | 22 (96) |
| HGBL (MYC and BCL6 translocations) | 1 (4) |
| Hans algorithm | |
| Non-GC | 18 (86) |
| GC | 3 (14) |
| Extranodal involvement | 19 (83) |
| CNS involvement | 3 (13) |
| Serum IgM level, median (range), g/L | 6.1 (0-31.1) |
| Ann Arbor stage III-IV | 22 (96) |
| IPI ≥3 | 10/20 (50) |
| Number of lines for HT, median (range) | 2 (1-4) |
| Characteristics at lymphodepletion | |
| Age at lymphodepletion, median (range), y | 66 (41-82) |
| >70 y | 8 (35) |
| Refractory to last therapy | 11 (48) |
| ECOG performance status ≥2 | 5/22 (23) |
| Elevated LDH | 11 (48) |
| Ann Arbor stage III-IV | 12/15 (80) |
| CNS involvement | 2/23 (9) |
| Bridging therapy | 17 (74) |
| Response to bridging therapy (n = 17) | |
| CR | 3 (18) |
| PR | 3 (18) |
| SD | 5 (29) |
| PD | 6 (35) |
| Lymphodepleting chemotherapy | |
| Flu/Cy | 20 (87) |
| Bendamustine | 3 (13) |
| CAR T-cell product | |
| Axicabtagene-ciloleucel | 14 (61) |
| Tisagenlecleucel | 9 (39) |
| Outcome after CAR-T infusion | |
| Best OR | 22 (96) |
| Best CR | 20 (87) |
| 1-y PFS (95% CI), % | 73.4 (50.2-87.1) |
| 1-y OS (95% CI), % | 80.5 (50.6-89.2) |
| Grade ≥3 CRS | 2 (9) |
| Grade ≥3 ICANS | 2 (9) |
| Variable . | Patients (n = 23) . |
|---|---|
| Sex: male/female (ratio) | 12/11 (1.1) |
| WM characteristics | |
| Age at WM diagnosis, median (range), y | 58 (35-72) |
| MYD88L265P mutation | 12/14 (86) |
| CXCR4 mutation | 2/8 (25) |
| Number of lines for WM, median (range) | 1 (0-4) |
| HT characteristics | |
| Age at HT, median (range), y | 65 (41-81) |
| Histology | |
| DLBCL, not otherwise specified | 22 (96) |
| HGBL (MYC and BCL6 translocations) | 1 (4) |
| Hans algorithm | |
| Non-GC | 18 (86) |
| GC | 3 (14) |
| Extranodal involvement | 19 (83) |
| CNS involvement | 3 (13) |
| Serum IgM level, median (range), g/L | 6.1 (0-31.1) |
| Ann Arbor stage III-IV | 22 (96) |
| IPI ≥3 | 10/20 (50) |
| Number of lines for HT, median (range) | 2 (1-4) |
| Characteristics at lymphodepletion | |
| Age at lymphodepletion, median (range), y | 66 (41-82) |
| >70 y | 8 (35) |
| Refractory to last therapy | 11 (48) |
| ECOG performance status ≥2 | 5/22 (23) |
| Elevated LDH | 11 (48) |
| Ann Arbor stage III-IV | 12/15 (80) |
| CNS involvement | 2/23 (9) |
| Bridging therapy | 17 (74) |
| Response to bridging therapy (n = 17) | |
| CR | 3 (18) |
| PR | 3 (18) |
| SD | 5 (29) |
| PD | 6 (35) |
| Lymphodepleting chemotherapy | |
| Flu/Cy | 20 (87) |
| Bendamustine | 3 (13) |
| CAR T-cell product | |
| Axicabtagene-ciloleucel | 14 (61) |
| Tisagenlecleucel | 9 (39) |
| Outcome after CAR-T infusion | |
| Best OR | 22 (96) |
| Best CR | 20 (87) |
| 1-y PFS (95% CI), % | 73.4 (50.2-87.1) |
| 1-y OS (95% CI), % | 80.5 (50.6-89.2) |
| Grade ≥3 CRS | 2 (9) |
| Grade ≥3 ICANS | 2 (9) |
Data are given as number/total (percentage) or number (percentage) unless otherwise indicated.
CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; Fly/Cy, fludarabine cyclophosphamide; GC, germinal center; HGBL, high-grade B-cell lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; OR, overall response; PD, progressive disease; SD, stable disease.